In the Johns Hopkins cohort, there was a 4-fold higher frequency of cancer in the anti–TIF1-γ–only group compared with patients who produced any of the 10 autoantibodies; cancer emerged in 37% of patients with anti–TIF1-γ only versus 9% with anti–TIF1-γ “plus” within 5 years, 34% versus 7% within 3 years, and 27% versus 4% within 1 year. Here, TRIM33 is linked to cancer.